Suppr超能文献

单纯外照射放疗治疗局限性前列腺癌:血清前列腺特异性抗原驱动的结果分析

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.

作者信息

Lee W R, Hanks G E, Schultheiss T E, Corn B W, Hunt M A

机构信息

Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, PA 19111.

出版信息

J Clin Oncol. 1995 Feb;13(2):464-9. doi: 10.1200/JCO.1995.13.2.464.

Abstract

PURPOSE

To determine the 5-year rate of survival with no evidence of disease (NED) using strict biochemical criteria in men with prostate cancer treated by external-beam radiotherapy alone and to examine possible clinical and treatment factors that predict the likelihood of NED survival.

MATERIALS AND METHODS

Five hundred men with clinically localized prostate cancer consecutively treated with external-beam radiotherapy alone with no prior, concomitant, or adjuvant endocrine therapy were identified. All patients had serial serum prostate-specific antigen (PSA) values determined after treatment and 451 patients had pretreatment PSA values determined. The median follow-up duration is 20 months (range, 2 to 72; mean, 36).

RESULTS

The 5-year rate of overall survival in this group of patients was 80%. The 5-year rate of survival without clinical evidence of disease (cNED) was 72%. The 5-year rate of survival without evidence of clinical, radiographic, or biochemical relapse (bNED) was 51%. Multivariate analysis demonstrated that a pretreatment serum PSA level < or = 15 ng/mL was the most important predictor of bNED survival (P < .0001). Patients with early-stage (T1, T2a/b) tumors and a pretreatment serum PSA less than 15 ng/mL had a 3-year rate of bNED survival of 86%. The rate of bNED survival for patients with a pretreatment PSA level greater than 15 ng/mL was 38% at 3 years.

CONCLUSION

Pretreatment serum PSA level is the most important predictor of treatment outcome in this group of patients treated with definitive radiotherapy alone. External-beam radiation alone can produce acceptable early rates of bNED survival in patients with clinically organ-confined tumors and a pretreatment PSA level < or = 15 ng/mL. To produce acceptable results in those patients with pretreatment PSA levels more than 15 ng/mL, effective adjuvant treatments in addition to aggressive local treatments are necessary.

摘要

目的

采用严格的生化标准确定单纯接受外照射放疗的前列腺癌男性患者5年无疾病证据(NED)生存率,并研究可能预测NED生存可能性的临床和治疗因素。

材料与方法

确定500例单纯接受外照射放疗、未接受过先前、同期或辅助内分泌治疗的临床局限性前列腺癌男性患者。所有患者在治疗后均测定了系列血清前列腺特异性抗原(PSA)值,451例患者测定了治疗前PSA值。中位随访时间为20个月(范围2至72个月;平均36个月)。

结果

该组患者的5年总生存率为80%。无临床疾病证据(cNED)的5年生存率为72%。无临床、影像学或生化复发证据(bNED)的5年生存率为51%。多变量分析表明,治疗前血清PSA水平≤15 ng/mL是bNED生存的最重要预测因素(P<0.0001)。早期(T1、T2a/b)肿瘤且治疗前血清PSA低于15 ng/mL的患者3年bNED生存率为86%。治疗前PSA水平大于15 ng/mL的患者3年bNED生存率为38%。

结论

在这组单纯接受根治性放疗的患者中,治疗前血清PSA水平是治疗结果的最重要预测因素。对于临床器官局限性肿瘤且治疗前PSA水平≤15 ng/mL的患者,单纯外照射放疗可产生可接受的早期bNED生存率。对于治疗前PSA水平大于15 ng/mL的患者,除积极的局部治疗外,还需要有效的辅助治疗才能产生可接受的结果。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验